The antiangiogenic mechanisms of action of thalidomide is the inhibition of VEGF, bFGF, and TGF-β signaling, which has been shown to contribute to the anti-inflammatory and anti-tumor effects of the drug [9, 25–27]. This evidence concerns the gene TGFB1 and neoplasm.